Literature DB >> 7212806

A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease.

C L Day, A J Sober, A W Kopf, R A Lew, M C Mihm, P Hennessey, F M Golomb, M N Harris, S L Gumport, J W Raker, R A Malt, A B Cosimi, W C Wood, D F Roses, F Gorstein, A Postel, W R Grier, M N Mintzis, T B Fitzpatrick.   

Abstract

Thirteen variables were studied for their relative usefulness in predicting recurrent disease in 107 patients with clinical Stage I melanoma of the upper extremity. After a mean follow-up period of 54 months, the only patents who have had recurrent disease to date are those who primary lesions were located either on the hand or posterior upper arm. The five-year disease-free survival role for 44 patients with melanoma at these sites was 68%. None of 63 patients with melanoma located on the forearm of anterior upper arm have had recurrent disease (i.e., the five-year, disease-free survival rate was 100% (p = 0.00004), compared with the hand or posterior arm group). A Cox proportional hazards (multivariate) analysis demonstrated that two primary tumor histologic variable, thickness in millimeters and ulceration, interacted to produce the best prognostic model for those 44 patients with melanoma of the hand or posterior upper arm. Twenty-one patients with primary lesions at these sites had primary tumors less than 2.25 mm in thickness and no evidence of ulceration histologically. Their five-year, disease-free survival role was 95%. For the remaining 23 patients with primary tumors on the hand or posterior upper arm who had either histologic evidence of ulceration or primary tumors greater than or equal to 2.25 mm, the five-year disease-free survival rate was 37% (p = 0.002, compared with group nonulcerated, thin lesions). The excellent survival rate for patients with melanomas on the forearm or anterior upper arm was not completely explained by pathologic stage, by primary tumor thickness, or by histologic ulceration of the primary tumor.

Entities:  

Mesh:

Year:  1981        PMID: 7212806      PMCID: PMC1345096          DOI: 10.1097/00000658-198104000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  Cutaneous melanoma: a twenty-year retrospective study with clinicopathologic correlation.

Authors:  J D Franklin; V H Reynolds; D L Page
Journal:  Plast Reconstr Surg       Date:  1975-09       Impact factor: 4.730

2.  Clinicopathological correlations in a series of 117 malignant melanomas of the skin of adults.

Authors:  N LANE; R LATTES; J MALM
Journal:  Cancer       Date:  1958 Sep-Oct       Impact factor: 6.860

3.  Malignant Melanoma: A Study of 217 Cases: Part I: Epidemiology.

Authors:  G E Block; S W Hartwell
Journal:  Ann Surg       Date:  1961-12       Impact factor: 12.969

4.  A retrospective survey of 498 patients with malignant melanoma.

Authors:  R McLeod; N C Davis; J J Herron; R A Caldwell; J H Little; R L Quinn
Journal:  Surg Gynecol Obstet       Date:  1968-01

5.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

6.  Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.

Authors:  M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; S A Rosenberg
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

7.  Prognostic factors in cutaneous malignant melanoma in stage I. A clinical, morphological and multivariate analysis.

Authors:  J Eldh; B Boeryd; L E Peterson
Journal:  Scand J Plast Reconstr Surg       Date:  1978

8.  The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

Authors:  M A Gromet; W L Epstein; M S Blois
Journal:  Cancer       Date:  1978-11       Impact factor: 6.860

9.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma.

Authors:  C M Balch; S J Soong; T M Murad; A L Ingalls; W A Maddox
Journal:  Surgery       Date:  1979-08       Impact factor: 3.982

10.  Stage I melanoma of the limbs. Immediate versus delayed node dissection.

Authors:  U Veronesi; J Adamus; D C Bandiera; I O Brennhovd; E Caceres; N Cascinelli; F Claudio; R L Ikonopisov; V V Javorskj; S Kirov; A Kulakowski; J Lacour; F Lejeune; Z Mechl; A Morabito; I Rodé; S Sergeev; E van Slooten; K Szczygiel; N N Trapeznikov; R I Wagner
Journal:  Tumori       Date:  1980-06-30
View more
  18 in total

1.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.

Authors:  Gulsun Erdag; Jochen T Schaefer; Mark E Smolkin; Donna H Deacon; Sofia M Shea; Lynn T Dengel; James W Patterson; Craig L Slingluff
Journal:  Cancer Res       Date:  2012-01-19       Impact factor: 12.701

Review 2.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

3.  Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Authors:  Anna E Vilgelm; C Andrew Johnson; Nripesh Prasad; Jinming Yang; Sheau-Chiann Chen; Gregory D Ayers; Jeff S Pawlikowski; Dayanidhi Raman; Jeffrey A Sosman; Mark Kelley; Jeffrey A Ecsedy; Yu Shyr; Shawn E Levy; Ann Richmond
Journal:  J Natl Cancer Inst       Date:  2015-12-30       Impact factor: 13.506

4.  Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat.

Authors:  C L Day; T J Harrist; F Gorstein; A J Sober; R A Lew; R J Friedman; B S Pasternack; A W Kopf; T B Fitzpatrick; M C Mihm
Journal:  Ann Surg       Date:  1981-07       Impact factor: 12.969

5.  Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression.

Authors:  H J Wanebo; P H Cooper; R W Hagar
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

6.  Judging prognosis in malignant melanoma of the skin. A problem of inference over small data sets.

Authors:  M S Blois; R W Sagebiel; M S Tuttle; T M Caldwell; H W Taylor
Journal:  Ann Surg       Date:  1983-08       Impact factor: 12.969

7.  Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions.

Authors:  C L Day; M C Mihm; A J Sober; M N Harris; A W Kopf; T B Fitzpatrick; R A Lew; T J Harrist; F M Golomb; A Postel; P Hennessey; S L Gumport; J W Raker; R A Malt; A B Cosimi; W C Wood; D F Roses; F Gorstein; D Rigel; R J Friedman; M M Mintzis
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

8.  A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.

Authors:  C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

9.  Prognostic significance in malignant melanoma of nuclear DNA content measured by a microfluorimetric method.

Authors:  Y Umebayashi; F Otsuka
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

10.  Acral lentiginous melanoma. A clinicopathologic entity.

Authors:  E T Krementz; R J Feed; W P Coleman; C M Sutherland; R D Carter; M Campbell
Journal:  Ann Surg       Date:  1982-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.